tbuckley/cabot-search huggingface dataset:
Breast cancer detection among Irish BRCA1 and BRCA2 mutation carriers.
Authors: Elaine Walsh, Michael P. Farrell, Fergal Gallagher, Roisin Clarke, Carmel Nolan, M. John Kennedy, Peter Daly, John McCaffrey, Elizabeth M. Connolly, Terence Boyle, Malcolm R. Kell, Sylvia O'Keefe, David J Gallagher
Journal: Journal of Clinical Oncology (2012)

e12038 Background: High-risk breast cancer screening for BRCA1/2 mutations carriers with clinical breast exam, mammography and MRI have sensitivities approaching 100%. Even with intensive screening BRCA mutation carriers can present with self-detected interval cancers. We investigate screening practices and presentation among a cohort of Irish BRCA1/2 mutation carriers. Methods: Females with breast cancer belonging to kindreds now known to harbour BRCA1/2 mutations were retrospectively identified. Records were reviewed for BRCA mutation, demographics, breast cancer diagnosis, stage, histology and screening. We assessed screening modalities and whether breast cancers were diagnosed at screening or as interval cancers. Results: 53 cases of breast cancer were diagnosed from 1968-2010 among 53 Irish hereditary breast ovarian cancer kindreds. BRCA mutation status was unknown at time of diagnosis but subsequently confirmed. Detection method was identified in 50% of patients: 84% by clinical breast exam (CBE), 4% mammography, 4% MRI and 8% by a combination of CBE and mammography. Fifteen women (28%) developed second breast cancer; 9(60%) were undergoing screening, 2 were not and 27% were unknown. 22% were detected by CBE alone; 34% mammography; 22% a combination of mammography and CBE and 22% by MRI. In 41%, histology changed between first and second diagnosis. Two women developed a third breast cancer. In one, her second was an interval cancer despite being in a screening programme. Her third was radiologically detected. Conclusions: In this cohort of Irish BRCA1/2 mutation carriers almost 25% of second breast cancers were not detected by screening. 4% of cases were phenocopies and in 41% histology changed between first and second diagnosis. [Table: see text]
Antithrombotic Activity of PRT54021, a Potent Oral Direct Factor Xa Inhibitor, Can Be Monitored Using a Novel Prothrombinase Inhibition Bioassay.
Authors: Uma Sinha, Susan T. Edwards, Paul W. Wong, Suzanne M. Delaney, Nisha Nanda, Ulla M. Marzec, Yvonne Pak, Stanley J. Hollenbach, Stephen R. Hanson
Journal: Blood (2006)
298O The clinical significance of deregulated cyclin E1 in high grade serous ovarian cancer (HGSOC)
Authors: D. Aziz, D. Etemadmoghadam, G. Au-Yeung, A. Muranyi, I. Gresshoff, M. Christie, R.A. Hutchinson, D. Ferraro, S. Stanislaw, L.A. Henricksen, None Tubbs, K. Shanmugam, D. Bowtell, P.M. Waring
Journal: Annals of Oncology (2016)
Mobilization as a Preparative Regimen for Hematopoietic Stem Cell (HSC) Transplantation in Rhesus Macaques.
Authors: Andre Larochelle, Cynthia L. Perez, Allen Krouse, Mark Metzger, Simon Fricker, Gary Bridger, Donald Orlic, Robert E. Donahue, Janis L. Abkowitz, Cynthia E. Dunbar
Journal: Blood (2005)
Annals Graphic Medicine - A Pill Person
Authors: Satyajeet Roy
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 February 2017Annals Graphic Medicine - A Pill PersonFREESatyajeet Roy, MDSatyajeet Roy, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G16-0025 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G16-0025.Author Information: Dr. Roy is Associate Professor of Medicine at the Cooper Medical School of Rowan University, Camden, New Jersey;an internal medicine-primary care physician at the Cooper University Healthcare, Cherry Hill, New Jersey; and the Director of the Cooper University Hospital Internal Medicine Residency Research Program. He believes that art can be a powerful medium of presenting complex human interactions and emotions through a simple and convenient constellation of lines, curves, and shades.Corresponding Author: Satyajeet Roy, MD, Cooper University Hospital, 1103 North Kings Highway, Suite 203, Cherry Hill, NJ 08034; e-mail, [email protected]edu.Author Contributions: Conception and design: S. RoyDrafting of the article: S. Roy.Critical revision for important intellectual content: S. Roy.Final approval of the article: S. Roy. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 February 2017Volume 166, Issue 3Page: W3-W4KeywordsDisclosureEmotionsHealth careHealth information technologyHospital medicineResidency ePublished: 7 February 2017 Issue Published: 7 February 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Pan-BCL-2 Family Small Molecule Inhibitor GX015-070 (GeminX, Inc.) Exhibits Single Agent Cytotoxicity, Is Synergistic with Select Anti-Leukemia Cytotoxic Agents, and Induces Apoptosis in Cell Lines with t(4;11)(q21;q23) Translocations.
Authors: Jessicca M. Rege, Blaine W. Robinson, Manish Gupta, Jeffrey S. Barrett, Peter C. Adamson, Kathryn C. Behling, Andrew D. Bantly, Jonni S. Moore, Carolyn A. Felix
Journal: Blood (2005)
TMOD-18. THREE-DIMENSIONAL MICROTUMORS IN PHYSIOLOGIC MICROENVIRONMENTS MAINTAIN BRAIN TUMOR INITIATING CELLS
Authors: Ashley Gilbert, Kiera Walker, Anh Tran, Yancey Gillespie, Raj Singh, Anita Hjelmeland
Journal: Neuro-Oncology (2016)

Elucidation of mechanisms of brain tumor initiating cell (BTIC) maintenance and therapeutic resistance offers great promise for development of novel anti-tumor treatments. Current leading studies rely on BTIC isolation from patient-derived xenografts followed by propagation as neurospheres. As this process is expensive and time-consuming, we determined if three-dimensional microtumors were an alternative in vitro method for modeling tumor growth via BITC maintenance and/or enrichment. Brain tumor cells were grown as neurospheres or as microtumors produced using a human-derived biomatrix HuBiogelTM and maintained with physiologically relevant microenvironments. Percentages of BITCs were then determined based on cell surface marker expression (CD133), label retention (carboxyfluorescein succinimidyl ester; CFSE), and tumorsphere formation capacity. Our data demonstrate that expansion of brain tumor cells as hypoxic and nutrient restricted microtumors significantly increased the percentage of both CD133+ and CFSE+ cells. For example, fifteen percent of all brain tumor cells from a xenograft propagated as microtumors were CD133+, whereas only one percent of neurosphere cultured cells expressed the BTIC marker. Relative to CD133, CFSE was retained in a higher percentage of cells, but CFSE+ cells were still increased in the microtumor condition in comparison to neurospheres. We further demonstrate that BTIC-marker positive cells isolated from microtumors maintain neurosphere formation capacity in the in vitro limiting dilution assay and tumorigenic potential in vivo. These data demonstrate that microtumors can be a useful three-dimensional biological model for the study of BTIC maintenance and targeting.
Roflumilast Ameliorates Ovalbumin-Induced Neutrophilic Airway Inflammation in Mice: Role of CD4+ CD25+ FOXP3+ Regulatory T-Cells
Authors: Mohamed G. Elsakkar, Olla A. Sharaki, Dina M. Abdallah, Dalia K. Mostafa, Fadia T. Shekondali
Journal: Journal of Allergy and Clinical Immunology (2017)
Nurse and nurse practitioner use and satisfaction of an online survivorship care plan builder.
Authors: Carolyn Vachani, Margaret K. Hampshire, Christine Hill-Kayser, Karen Arnold-Korzeniowski, Christina Bach, James M. Metz
Journal: Journal of Clinical Oncology (2016)

58 Background: A cornerstone to cancer survivorship care is the education provided to patients regarding late and long-term effects, follow up care, and healthy living after a cancer diagnosis and treatment. Nurses have long provided patient education in oncology care. The provision of survivorship care is a natural extension of this role. An online survivorship care plan (SCP) builder can facilitate this and reduce the resources required for implementation of a survivorship program. Methods: We examined nurse and nurse practitioner (NP) use and satisfaction of two free online SCP builders, OncoLife on http://www.oncolink.org , and the LIVESTRONG Care Plan, between May 2010 and July 2015. Users of the program were queried about their satisfaction with the information provided, if their practice had an established survivorship program and if they would use the program for other patients. Time to complete a SCP was measured. Results: Healthcare providers completed 16,302 SCPs during the timeframe examined. The majority of plans were completed by nurses (n = 7393, 45%) and nurse practitioners (NPs) (n = 6296, 39%), while the remaining were completed by physicians (n = 754, 5%) and unknown users (n = 1859, 11%). When compared to University-based cancer centers (UCC), SCPs completed in community settings were more often delivered by nurses, as opposed to NPs (UCC: Nurses 22%, NPs 53%; community setting: Nurses 57%, NPs 31%; p &lt; 0.001). A satisfaction survey was completed by 415 Nurse and NP users. They reported high satisfaction with the information provided (31% excellent, 33% very good, 26% good); 75% reported that the plan provided “just enough information”, whereas 11% felt it “could use more information”, and 6% felt there was “too much information”. Sixty-four percent had an established survivorship program and 100% would use it for other patients. The median time to complete an SCP was 4 min 17 sec (IQR 2:38-7:19). Conclusions: Nurse and NP users report high satisfaction using an online SCP builder. In community settings, nurses were completing the plan significantly more often than NPs. The short time required to create the SCPs may allow practices to efficiently meet regulatory requirements with minimal resources.
Splenic Sinusoids Stimulate the Survival and Proliferation of Hairy Cell Leukemia B Cells through BAFF, APRIL and Heparan-Sulphate Proteoglycans.
Authors: April Chiu, Weifeng Xu, Bing He, Paul Santini, Stacey R. Dillon, Amy Chadburn, Daniel M. Knowles, Andrea Cerutti
Journal: Blood (2006)
P17.01 Clinical profile and treatment outcomes of patients with primary CNS lymphoma in a tertiary hospital in the Philippines: An eight-year retrospective review
Authors: M. A. Sales, J. P. Batara
Journal: Neuro-Oncology (2016)

Primary CNS Lymphoma (PCNSL) is an unusual extranodal form of Non-Hodgkin’s lymphoma with a locally aggressive course but a rare tendency to disseminate systemically. It has been documented in that the clinical characteristics and response to treatment among Asians is comparable to the Western population yet no studies done locally are available. This study aims to determine the clinico-pathologic profile of patients diagnosed with PCNSL seen at Philippine General Hospital (PGH) from January 2006 to September, 2014 and to evaluate the patients’ response to the following treatment modalities: 1) Combination chemotherapy 2) Chemo-RT 3) Single agent chemotherapy and 4) no specific anti-lymphoma treatment. This is a descriptive and retrospective study that included all cases of histologically-proven PCNSL seen at the PGH from January 2006 to September, 2014. The clinical profile, imaging studies and biopsy findings were obtained from the patient records. The survival rates at the end of one and two years of diagnosis were computed. Among patients diagnosed with PCNSL at PGH, there is a higher incidence of PCNSL among males with a male to female ratio of 1.4:1 and have a younger onset with a median age of 50.2 years. Most patients presented with signs of increase ICP and majority had solitary cortical lesions with histopathologic diagnosis of diffuse large B cell lymphoma. Patients who did not undergo any form of treatment had a mean survival of 10 months. Immunocompromised patients had a shorter life-span with a mean survival of 7.5 months. Treatment of combination chemotherapy with HD-MTX and Rituximab had the most favorable outcome followed by HD-MTX only with a 2 year survival rate of 100% and 66% respectively while patients who underwent chemo-RT had a 2 year survival rate of 33% with a high incidence of neurocognitive delay.
Distance From Home to the Nearest Tobacco Outlet May Not Reflect the True Accessibility—Reply
Authors: Anna Pulakka, Ichiro Kawachi, Mika Kivimäki
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Margaret McCartney: Charging patients won’t solve the NHS’s problems
Authors: Margaret McCartney
Journal: BMJ (2017)

It’s back: let’s charge patients for GP appointments. This idea floats to the surface every so often, like steatorrhoea. Think tanks propose it like clockwork, and then up it bubbles into headlines.12 GPs are surveyed, some of whom think that it will get rid of “trivial” consultations.3 Others say that it will balance the books.4

Now we have the leader of a local medical committee proposing charges for any routine appointments done outside office hours.5 In Northern Ireland the stress on primary care …
The role of a geriatrician in a cancer center.
Authors: Beatriz Korc-Grodzicki, Sung W. Sun, Armin Shahrokni, Koshy Alexander, Soo Jung Kim, Sincere McMillan, George J. Bosl
Journal: Journal of Clinical Oncology (2016)

39 Background: Older adults are likely to have coexisting health conditions, polypharmacy and functional limitations. The geriatrician may have a pivotal role in risk assessment, prevention and treatment of comorbidities and addressing geriatric syndromes. The purpose of this study is to describe the growth and development of, and the role of a Geriatrics Service (GS) in a cancer center. Methods: A GS was founded in MSKCC in 2009. Since then it has grown to provide inpatient (IP) and outpatient (OP) care for older adults undergoing cancer diagnosis, surveillance or active treatment. It offers preoperative evaluations, geriatric assessment (GA) and follow-up shared- care. Recently, a Transitional Care Management (TCM) program was established for patients at increased risk of rehospitalization. The GS strives to develop an interprofessional educational geriatrics curriculum and to participate in quality and research projects focused on cancer and aging. Results: Between 2009 and 2014 a total of 6679 new patients were evaluated by the GS. 16% of the patients were 65-75, 70% were 76-85 and 14% were older than 85. 46% were male and 84% were white. 15% were IP and 85% were OP consultations. 13% of the OP consults were for GA, the rest were preoperative evaluations. All patients seen preoperatively who are admitted after surgery, are followed postoperatively by the IP geriatrics team. In total, 4 Geriatricians, 2 Geriatric Nurse Practitioners (GNP) and 3 RNs were recruited. The number of follow-up visits increased from 143 in 2009 to 733 in 2014. The new TCM program based on close communication between the IP and OP GNP has been successful in keeping frail patients from frequent rehospitalizations. Noon conferences on geriatrics for the house staff, a biannual course on “Advancing Nursing Expertise in the Care of Older Adults with Cancer” and a monthly interprofessional meeting for the discussion of Geriatric Clinical Complex Cases (GCCC) are ongoing. Research has focused on risk assessment and the use of telemedicine in geriatric patient care. Conclusions: The establishment of a GS in a cancer center was very well received and embraced by the oncologists showing an unmet need in the care of the older cancer patient. The potential reproducibility beyond the cancer center will be discussed.
Skap2 is required for β2 integrin–mediated neutrophil recruitment and functions
Authors: Mark Boras, Stephanie Volmering, Arne Bokemeyer, Jan Rossaint, Helena Block, Bernadette Bardel, Veerle Van Marck, Barbara Heitplatz, Stefanie Kliche, Annegret Reinhold, Clifford Lowell, Alexander Zarbock
Journal: The Journal of Experimental Medicine (2017)

Integrin activation is required for neutrophil functions. Impaired integrin activation on neutrophils is the hallmark of leukocyte adhesion deficiency (LAD) syndrome in humans, characterized by impaired leukocyte recruitment and recurrent infections. The Src kinase–associated phosphoprotein 2 (Skap2) is involved in integrin functions in different leukocyte subtypes. However, the role of Skap2 in β2 integrin activation and neutrophil recruitment is unknown. In this study, we demonstrate the crucial role of Skap2 in regulating actin polymerization and binding of talin-1 and kindlin-3 to the β2 integrin cytoplasmic domain, thereby being indispensable for β2 integrin activation and neutrophil recruitment. The direct interaction of Skap2 with the Wiskott–Aldrich syndrome protein via its SH3 domain is critical for integrin activation and neutrophil recruitment in vivo. Furthermore, Skap2 regulates integrin-mediated outside-in signaling events and neutrophil functions. Thus, Skap2 is essential to activate the β2 integrins, and loss of Skap2 function is sufficient to cause a LAD-like phenotype in mice.
Efficacy and Safety of Promace-Cytabom Regimen with Sandwiched Radiotherapy Method in the Treatment of Newly Diagnosed, Stage IE to IIE, Extranodal NK/T-Cell Lymphoma, Nasal Type
Authors: Young-Woo Jeon, Sung-Soo Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-je Kim, Seok Lee, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Seok-Goo Cho
Journal: Blood (2016)
Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability
Authors: K.H. Jung, B. Ataseven, M. Verrill, X. Pivot, M. De Laurentiis, N. Al-Sakaff, S. Lauer, M. Shing, J. Gligorov, H.A. Azim
Journal: Annals of Oncology (2016)
Regulatory role of the JAK STAT kinase signalling system on the IL-23/IL-17 cytokine axis in psoriatic arthritis
Authors: Smriti K Raychaudhuri, Christine Abria, Siba P Raychaudhuri
Journal: Annals of the Rheumatic Diseases (2017)

We read with great interest the article by Gao et al .1 They have reported the regulatory role of the JAK/STAT kinase system on the inflammatory/proliferative cascades for pannus formation in psoriatic arthritis (PsA) such as on fibroblast like synovial cells (FLS) biology and on secretion of inflammatory cytokines (interleukin (IL) 6, IL-8, monocyte chemoattractant protein (MCP)-1) by these FLS. Tofacitinib targets JAK1 and JAK2 with IC50 values in the same order of magnitude as that of JAK3.2 They have also provided the mechanisms of actions of tofacitinib by demonstrating that tofacitinib significantly decreased pSTAT3, pSTAT1, NFκBp65 in PsAFLS and inhibits the cellular and molecular events of pannus formation. However, Gao et al did not address a critical issue whether JAK/STAT signalling system regulates the IL-23/IL-17 cytokine axis in PsA. Here we are sharing an alternative mechanism for the role of JAK/STAT kinase system in the pathogenesis of PsA.

Aberrant activation of IL-23/IL-17 cytokine axis is a dominant pathology in PsA. …
New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma.
Authors: Viktor Grünwald, Steffen Weikert, Ingo GH Schmidt-Wolf, Stefan Hauser, Marina Tschaika, Ekaterina Weith, Matthias Schroff, Manuel Schmidt, Burghardt Wittig
Journal: Journal of Clinical Oncology (2012)

398 Background: The purpose of this first-in-man phase 1-2 study is to assess safety and efficacy of treatment with investigational drug MGN1601 in patients with advanced renal cell carcinoma. MGN1601 consists of two active ingredients: genetically modified allogeneic (human) cells transfected with four different MIDGE vectors encoding IL-7, GM-CSF, CD80 and CD154 and a synthetic DNA-based immunomodulator dSLIM-30L1, a TLR-9 agonist, acting as adjuvant. Methods: The ASET study is conducted as multicenter, open, single-arm phase 1-2 study. The study therapy consists of 8 MGN1601 treatments administered as follows: the first 3 treatments are administered weekly, and the consecutive 5 treatments bi-weekly. Patients who achieve disease control are proposed to continue the therapy in an extension phase. Such patients receive 5 further applications up to week 120. In this study, safety and efficacy of the study treatment will be evaluated based on extensive clinical and laboratory assessments, monitoring of patients’ quality of life, immunological tests, and radiological investigations. Results: Eighteen patients have been included into the study so far and received up to 9 treatments with MGN1601. Eight patients completed the 12 week treatment per protocol (TPP). Two of these patients (25% of TPP) achieved disease control (one PR and one SD) after 12 weeks and currently continue the treatment in the extension phase. 48 adverse events were reported during the treatment phase. Of them, 10% were judged as possibly related, 23% unlikely and 67% as not drug-related by the investigators. Possible adverse events include mild fever, edema of the ankle, exanthema crook of the arm, pruritus crook of the arm and arthralgia intermittent. The therapy is well tolerated – no treatment-limiting toxicities or grade 2–4 toxicities occurred in these patients. Conclusions: The results of the clinical study in late stage RCC patients show promising efficacy and a favourable safety profile of the cell-based tumor vaccine consisting of genetically modified allogeneic transfected RCC cells and the immunomodulator.
US cardiologist is sentenced to prison for plot to kill rival doctor
Authors: Owen Dyer
Journal: BMJ (2017)

A Long Island cardiologist who offered prescription drugs to pay men to beat and potentially kill a rival doctor and set fire to his clinic has been sentenced to five years in prison and five years supervision upon release.1

Anthony Moschetto, 56, was “a wannabe Mafioso in a doctor’s jacket” who was caught when he sought to enlist the services of men he thought were criminals but who …
Diving Suit: Sterile, Ambulatory, Personnal Device for Protective and Preventive Isolation of Nosocomial Invasive Fungal Infections (IFI) in Neutropenic Patients Hospitalised in Laminar Air Flow Room Who Need a Disruption of Isolation.
Authors: Anne Thiebaut, Michel Perraud, Denis Lyonnet, Samuel Ozil
Journal: Blood (2005)
Bortezomib, Dexamethasone and Concomitant or Sequential Thalidomide (VTD): An Effective Combination for Relapsed/Refractory Multiple Myeloma Failing Thalidomide and Dexamethasone.
Authors: Evren Ozdemir, Yener Koc, Ayse Kars, Alev Turker, Gulten Tekuzman, Emin Kansu
Journal: Blood (2007)